Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesSales of Property, Plant and EquipmentShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Gyre Therapeutics (GYRE) Change in Account Payables (2016 - 2025)

Historic Change in Account Payables for Gyre Therapeutics (GYRE) over the last 12 years, with Q3 2025 value amounting to $483000.0.

  • Gyre Therapeutics' Change in Account Payables rose 162500.0% to $483000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $256000.0, marking a year-over-year increase of 26100.63%. This contributed to the annual value of -$245000.0 for FY2024, which is 15764.71% down from last year.
  • Latest data reveals that Gyre Therapeutics reported Change in Account Payables of $483000.0 as of Q3 2025, which was up 162500.0% from -$51000.0 recorded in Q2 2025.
  • In the past 5 years, Gyre Therapeutics' Change in Account Payables registered a high of $6.3 million during Q4 2022, and its lowest value of -$3.7 million during Q2 2022.
  • Its 5-year average for Change in Account Payables is $53368.4, with a median of -$23000.0 in 2024.
  • As far as peak fluctuations go, Gyre Therapeutics' Change in Account Payables plummeted by 71311.48% in 2021, and later skyrocketed by 162500.0% in 2025.
  • Quarter analysis of 5 years shows Gyre Therapeutics' Change in Account Payables stood at $2.6 million in 2021, then skyrocketed by 144.48% to $6.3 million in 2022, then crashed by 101.66% to -$104000.0 in 2023, then plummeted by 82.69% to -$190000.0 in 2024, then skyrocketed by 354.21% to $483000.0 in 2025.
  • Its last three reported values are $483000.0 in Q3 2025, -$51000.0 for Q2 2025, and $14000.0 during Q1 2025.